Preview

Translational Medicine

Advanced search

Role of 11C-choline PET/CT in parathyroid adenomas’ localization in patients with primary hyperparathyroidism

https://doi.org/10.18705/2311-4495-2023-10-2-88-95

Abstract

Background. Topical diagnosis of primary hyperparathyroidism (PHPT) remains an urgent problem due to the high incidence of persistence and recurrence after surgical treatment. At the preoperative stage, a search for the parathyroid hormone hyperproduction source is performed using instrumental methods: ultrasound, scintigraphy of the parathyroid glands (PTG) and multislice computed tomography (MSCT). The cause of PHPT persistence and recurrence after parathyroidectomy may be the multiple nature of PTG lesions or their ectopic location. Additional methods of visualization of PTG adenomas can be used to improve diagnosis (PET/CT).

Objective. To compare the sensitivity and specificity of PET/CT with 11C-choline with the traditional visualization techniques.

Design and methods. 16 PHPT patients were analyzed. All patients underwent US, subtraction scintigraphy with 99mTc-technetril/99mTc-pertechnitate and CT were performed in 12 and 16 patients, respectively. 11C-choline PET/CT was used for all patients. Imaging results’ coincidence of two methods were labeled as the true one.

Results. The sensitivity of PET/CT with 11C-choline was 94 %, CT, subtraction scintigraphy with 99mTc-technetril/99mTc-pertechnitate and US — 75 %, 69 % and 63 %, respectively. The specificity of PET/CT with 11C-choline, CT, scintigraphy with 99mTc-technetril/99mTc-pertechnitate, and US was 100 %, 84 %, 76 %, and 68 %, respectively.

Conclusion. PET/CT with 11C-choline demonstrated best sensitivity and specificity among all methods and can become an alternative in PHPT diagnostics in case of negative or inconvclusive results of previous visualization.

About the Authors

K. A. Pogosian
Almazov National Medical Research Centre
Russian Federation

Karina A. Pogosian, MD, Junior Researcher, Research Laboratory of Neuroendocrine Tumours, World-Class Research Centre for Personalized Medicine

Saint Petersburg



T. L. Karonova
Almazov National Medical Research Centre

Tatiana L. Karonova, MD, PhD, DSc, Professor, Department of Endocrinology, Leading Researcher, Head of Scientific Laboratory of Clinical Endocrinology, Institute of Endocrinology

Saint Petersburg



D. V. Ryzhkova
Almazov National Medical Research Centre

Daria V. Ryzhkova, MD, PhD, DSc, Professor, Department of Nuclear Medicine and Radiation Technology, Head of Clinical Research Department of Nuclear Medicine, Researcher, Department of the Nuclear Medicine and Theranostics

Saint Petersburg



L. G. Yanevskaya
Almazov National Medical Research Centre

Liubov G. Yanevskaya, MD, Junior Researcher, Clinical Endocrinology Laboratory

Saint Petersburg



U. A. Tsoy
Almazov National Medical Research Centre

Uliana A. Tsoy, MD, PhD, Head of Research Laboratory of Neuroendocrine Tumours, World-Class Research Centre for Personalized Medicine

Saint Petersburg



O. V. Yudina
Almazov National Medical Research Centre

Olga V. Yudina, MD, PhD, Associate Professor, Department of the Nuclear Medicine and Theranostics

Saint Petersburg



E. V. Ivanikha
Almazov National Medical Research Centre

Elena V. Ivanikha MD, PhD, surgeon, Department of Surgical Methods of Treatment of Cancer Patients

Saint Petersburg



E. N. Grineva
Almazov National Medical Research Centre

Elena N. Grineva, MD, PhD, DSc, Professor, Director of Institute of Endocrinology Chief Research Associate, Research Laboratory of Neuroendocrine Tumours, WorldClass Research Centre for Personalized Medicine

Saint Petersburg



References

1. Mokrysheva NG, Eremkina AK, Mirnaya SS, et al. The clinical practice guidelines for primary hyperparathyroidism, short version. Problems of Endocrinology. 2021; 67(4):94–124. In RussianDOI: 10.14341/probl12801.

2. Walker MD, Bilezikian JP. Primary Hyperparathyroidism. In: Feingold KR, Anawalt B, Blackman MR, et al. Endotext [Internet]. South Dartmouth (MA): MDText.com, Inc. https://www.ncbi.nlm.nih.gov/books/NBK278923/ (19 Apr 2021)

3. Cheung K, Wang TS, Farrokhyar F, et al. A metaanalysis of preoperative localization techniques for patients with primary hyperparathyroidism. Ann Surg Oncol. 2012; 19(2):577–583. DOI: 10.1245/s10434-011-1870-5.

4. Kunstman JW, Kirsch JD, Mahajan A, et al. Clinical review: Parathyroid localization and implications for clinical management. J Clin Endocrinol Metab. 2013; 98(3):902–912. DOI: 10.1210/jc.2012-3168.

5. Noureldine SI, Aygun N, Walden MJ, et al. Multiphase computed tomography for localization of parathyroid disease in patients with primary hyperparathyroidism: How many phases do we really need? Surgery. 2014; 156(6):1300–1306. DOI: 10.1016/j.surg.2014.08.002.

6. Habener JF, Maunus R, Dee PC, et al. Early events in the cellular formation of proparathyroid hormone. J Cell Biol. 1980; 85(2):292–298. DOI: 10.1083/jcb.85.2.292.

7. Beggs AD, Hain SF. Localization of parathyroid adenomas using 11C-methionine positron emission tomography. Nucl Med Commun. 2005; 26(2):133–136. DOI: 10.1097/00006231-200502000-00009.

8. Mathey C, Keyzer C, Blocklet D, et al. 18F-Fluorocholine PET/CT Is More Sensitive Than 11C-Methionine PET/CT for the Localization of Hyperfunctioning Parathyroid Tissue in Primary Hyperparathyroidism. J Nucl Med. 2022; 63(5):785–791. DOI: 10.2967/jnumed.121.262395.

9. Noltes ME, Kruijff S, Noordzij W, et al. Optimization of parathyroid 11C-choline PET protocol for localization of parathyroid adenomas in patients with primary hyperparathyroidism. EJNMMI Res. 2019; 9(1):73. DOI: 10.1186/s13550-019-0534-5.

10. Christensen JW, Ismail A, Søndergaard SB, et al. Preoperative imaging in primary hyperparathyroidism: Are 11 C-Choline PET/CT and 99m Tc-MIBI/123 Iodide subtraction SPECT/CT interchangeable or do they supplement each other? Clin Endocrinol (Oxf). 2022; 97(3):258–267. DOI: 10.1111/cen.14688.

11. Noltes ME, Kruijff S, Jansen L, et al. A retrospective analysis of the diagnostic performance of 11C-choline PET/ CT for detection of hyperfunctioning parathyroid glands after prior negative or discordant imaging in primary hyperparathyroidism. EJNMMI Res. 2021; 11(1):32. DOI: 10.1186/s13550-021-00778-7.

12. Liu Y, Dang Y, Huo L, et al. Preoperative Localization of Adenomas in Primary Hyperparathyroidism: The Value of 11C-Choline PET/CT in Patients with Negative or Discordant Findings on Ultrasonography and 99mTcSestamibi SPECT/CT. J Nucl Med. 2020; 61(4):584–589. DOI: 10.2967/jnumed.119.233213.


Review

For citations:


Pogosian K.A., Karonova T.L., Ryzhkova D.V., Yanevskaya L.G., Tsoy U.A., Yudina O.V., Ivanikha E.V., Grineva E.N. Role of 11C-choline PET/CT in parathyroid adenomas’ localization in patients with primary hyperparathyroidism. Translational Medicine. 2023;10(2):88-95. (In Russ.) https://doi.org/10.18705/2311-4495-2023-10-2-88-95

Views: 868


Creative Commons License
This work is licensed under a Creative Commons Attribution 4.0 License.


ISSN 2311-4495 (Print)
ISSN 2410-5155 (Online)